Axsome Therapeutics released impressive second quarter results this morning. The biggest positive was that ADVANCE 2 for Alzheimer's Agitation, is to be released second half of 2024.
- Auvelity for MDD sales totaled $65 million for the quarter
- A New Drug Application for AXS-07 has been submitted
- Alzheimer's Agitation phase 3, to be released 2nd half 2024
- ADHD phase 3 clinical trial results, 2nd half 2024
The stock had a wild day due to overall market volatility, recording a low of 72.21 early, but closed at 83.21 end of day, outperforming the broader market sell-off. Thank you for reading.
No comments:
Post a Comment